Back to Search Start Over

Early outcomes following transatrial transcatheter mitral valve replacement in patients with severe mitral annular calcification.

Authors :
Brener, Michael I.
Hamandi, Mohanad
Hong, Estee
Pizano, Alejandro
Harloff, Morgan T.
Garner, Evan F.
El Sabbagh, Abdallah
Kaple, Ryan K.
Geirsson, Arnar
Deaton, David W.
Islam, Ashequl M.
Veeregandham, Ramesh
Bapat, Vinayak
Khalique, Omar K.
Ning, Yuming
Kurlansky, Paul A.
Grayburn, Paul A.
Nazif, Tamim M.
Kodali, Susheel K.
Leon, Martin B.
Source :
Journal of Thoracic & Cardiovascular Surgery; Apr2024, Vol. 167 Issue 4, p1263-1263, 1p
Publication Year :
2024

Abstract

Implantation of a transcatheter valve-in-mitral annular calcification (ViMAC) has emerged as an alternative to traditional surgical mitral valve (MV) replacement. Previous studies evaluating ViMAC aggregated transseptal, transapical, and transatrial forms of the procedure, leaving uncertainty about each technique's advantages and disadvantages. Thus, we sought to evaluate clinical outcomes specifically for transatrial ViMAC from the largest multicenter registry to-date. Patients with symptomatic MV dysfunction and severe MAC who underwent ViMAC were enrolled from 12 centers across the United States and Europe. Clinical characteristics, procedural details, and clinical outcomes were abstracted from the electronic record. The primary end point was all-cause mortality. We analyzed 126 patients who underwent ViMAC (median age 76 years [interquartile range {IQR}, 70-82 years], 28.6% female, median Society of Thoracic Surgeons score 6.8% [IQR, 4.0-11.4], and median follow-up 89 days [IQR, 16-383.5]). Sixty-one (48.4%) had isolated mitral stenosis, 25 (19.8%) had isolated mitral regurgitation (MR), and 40 (31.7%) had mixed MV disease. Technical success was achieved in 119 (94.4%) patients. Thirty (23.8%) patients underwent concurrent septal myectomy, and 8 (6.3%) patients experienced left ventricular outflow tract obstruction (7/8 did not undergo myectomy). Five (4.2%) patients of 118 with postprocedure echocardiograms had greater than mild paravalvular leak. Thirty-day and 1-year all-cause mortality occurred in 16 and 33 patients, respectively. In multivariable models, moderate or greater MR at baseline was associated with increased risk of 1-year mortality (hazard ratio, 2.31; 95% confidence interval, 1.07-4.99, P =.03). Transatrial ViMAC is safe and feasible in this selected, male-predominant cohort. Patients with significant MR may derive less benefit from ViMAC than patients with mitral stenosis only. [Display omitted] [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00225223
Volume :
167
Issue :
4
Database :
Supplemental Index
Journal :
Journal of Thoracic & Cardiovascular Surgery
Publication Type :
Academic Journal
Accession number :
175961745
Full Text :
https://doi.org/10.1016/j.jtcvs.2022.07.038